The biotech sector has stumbled in recent months as investors have moved to take profits on the industry's boom. Daniel Koller, manager of the BB Biotech fund, outlines the new breed of drugs set to push the sector higher.
The Sovaldi effect The upward trend in the biotech sector from 2012 and 2013 continued in the first two months of this year. However, in March the sector reversed, pulled back by concerns on the pricing sustainability of Gilead's Sovaldi drug. Sovaldi, for treating Hepatitis C, offers higher cure rates with a better safety profile than current treatments, means that Gilead is strongly positioned in its pricing negotiations. Financial and clinical uptake data shows that Gilead's launch of Solvaldi has far exceeded market expectations. So far, Sovaldi looks set to become the big...
To continue reading this article...
Join Investment Week for free
Signup and gain exclusive members-only insights - all free of charge!
- Unlimited access to real-time news, analysis and opinion from the investment industry, including the Sustainable Hub covering fund news from the ESG space
- Get ahead of regulatory and technological changes affecting fund management
- Important and breaking news stories selected by the editors delivered straight to your inbox each day
- Weekly members-only newsletter with exclusive opinion pieces from leading industry experts
- Be the first to hear about our extensive events schedule and awards programmes
